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INTRODUCTION
A recent report by the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium identified a novel genetic locus at chromosome 17q25 associated with white matter hyperintensities (WMH) on MRI in stroke-free community individuals. 1, 2 WMH are common in stroke-free adults and increase with age. Prospective studies show WMH predict increased risks of cognitive decline, stroke and death. 3 One might expect risk factors for WMH in community populations to also confer increased risk of WMH in stroke patients. However, the underlying pathology of WMH is heterogeneous; small punctate lesions are associated with mixed etiologies, while more confluent areas correspond primarily to small vessel disease (SVD). 4 In stroke patients, WMH are more frequent and extensive compared with healthy age-matched individuals and are usually associated with SVD. 4 We hypothesized that risk factors for WMH in community populations without stroke also confer increased risk of WMH in stroke patients. Therefore, we assessed whether the 17q25 locus is associated with WMH as a quantitative trait in ischemic stroke. If the 17q25 locus acted to increase WMH through promotion of the small vessel arteriopathy, one might expect it to also increase risk of lacunar stroke, another SVD phenotype. To test this hypothesis, its association with lacunar stroke status was also examined in a cases-control analysis.
METHODS & MATERIALS

A. Association of 17q25 locus with WMHV Subjects
Stroke cases were recruited from one community-and 8 hospital-based cohorts of ischemic strokes with genome-wide association study (GWAS) data available as well as MRI scans for WMH volume (WMHV) measurement. Details of populations are in Table 1 . Inclusion criteria were: age>18 years, self-reported European ancestry, and a diagnosis of ischemic stroke of any subtype. Exclusion criteria were CADASIL, vasculitis, demyelinating and mitochondrial disorders.
Clinical characteristics
Hypertension was defined as antihypertensive prescription prior to stroke or systolic blood pressure >140 or diastolic >90mmHg more than one week post-stroke. Hypercholesterolemia was defined as lipid-lowering treatment prior to stroke, and/or elevated serum cholesterol (>5.2mmol/l) on stroke admission. Ever-smoker was defined as current and ex-smokers.
Diabetes was defined as a previous diagnosis of diabetes mellitus. Ischemic stroke cases were subtyped according to the TOAST criteria 5 or similar (Supplementary Table S1 ).
MRI analysis
MRI was acquired as part of routine clinical practice in stroke evaluation using different scanners at individual centers. Fluid attenuated inversion recovery (FLAIR) sequences were primarily used for WMH analysis; however, in their absence, T2 sequences were used (Supplementary Table S2 ).
WMHV was measured in the hemisphere contralateral to the acute infarction to avoid confounding by T2 hyperintense signal due to acute stroke. All supratentorial white matter and deep gray matter lesions were included in WMHV with the exception of WMH corresponding to lacunar infarcts. MRI scans with excessive movement artefact, incomplete brain coverage, or bihemispheric infarcts (other than lacunar) were excluded. To account for normal interindividual variability in head size, an estimate of total intracranial volume (TICV) was derived, using site-specific volumetric methodology.
Scans were analyzed anonymously, blinded to genetic information. MRIs from the
Massachusetts General Hospital (MGH), Ischemic Stroke Genetics Study (ISGS), and Australian
Stroke Genetics Collaborative (ASGC) studies were analyzed in Boston. FLAIR sequences were analyzed using a MRIcro (www.mricro.com) semi-automated method as previously described. 6 Using operator-mediated quality assurances, overlapping regions of interest (ROIs) corresponding to WMH produced the final maps for WMHV calculation. 6 To adjust for head size, intracranial area (ICA) was used as a validated marker of TICV. 7 The ICA constituted the average of two mid-sagittal slices traced using anatomical landmarks on T1 sequences. 7 SWISS scans were analyzed in the same way at the University of Virginia by the Boston-trained rater.
The Wellcome Trust Case Control Consortium-2 (WTCCC2) and Milan cohorts were analyzed in London using DISPunc semi-automated lesion drawing software 8 . A 'seed' at the lesion border was manually marked, following which the program automatically outlined the lesion based on the signal intensity gradient. Each ROI was visually inspected and manually corrected as required. To estimate TICV, T2 and, in its absence, FLAIR sequences were analyzed using an automated segmentation program, SIENAX 9 , and summing the cerebrospinal fluid, gray and white matter volumes.
WMH quantification agreement across the two main reading centers was performed for 50 randomly selected scans; agreement was very good (intraclass correlation coefficient 0.95, CI 0.91-0.97 n=50).
Genotyping
WTCCC2-UK and German cases were genotyped on the Illumina Human660W-Quad. Milan cases were genotyped using Illumina Human610-Quad or Human660W-Quad. ASGC samples were genotyped using the Human610-Quad. Both ISGS and SWISS samples were genotyped using the Illumina650K-Quad. MGH were genotyped on the Affymetrix 6.0, Illumina Human610-Quad or Illumina OmniExpress beadchips.
For all cohorts, individuals were removed if their inferred sex was discordant with the recorded sex or if >5% missing genotype data. Autosomal single nucleotide polymorphisms (SNPs) were excluded for minor allele frequency <1%, >5% missing data, or Hardy-Weinberg equilibrium p<1x10 -6 . Each center performed checks for relatedness and population stratification. After quality-control procedures there was an effective sample size of 2588.
Imputation was performed in all centers using IMPUTE2. 10 All centers were imputed to HapMap3 and 1000 Genomes Project Phase pilot (June 2010) with the exception of MGH Omni, which was imputed to 1000 Genomes Integrated Release (June 2011). Post imputation, poorly imputed SNPs (r 2 <0.3) were removed resulting in 2706548 SNPs common to all centers.
Genome-wide Analyses and Meta-Analyses
To account for differences in MRI image acquisitions and population characteristics, we used a joint-analysis strategy; each cohort was analyzed independently and then meta-analyzed. Stroke cases with T2 images were analyzed separately from the FLAIR images. MGH samples were also sub-grouped based on genotyping platform (Supplementary Table S2 ).
Single hemisphere WMHV was doubled to obtain whole brain values and adjusted for normal inter-individual variation in head size by multiplying by the ratio of mean TICV to individual TICV. Values were natural log-transformed to a normal distribution. Within each group, ranktransformed residuals were derived from a linear regression model predicting WMHV with age, sex, and the first two ancestry principle components as covariates in GenABEL. 11 Thus the phenotype was adjusted for age because WMHV is highly age-dependent. 3, 4 Principle components, derived using EIGENSTRAT (http://genepath.med.harvard.edu/~reich/Software.htm), were included to correct for potential population stratification. GWA analysis was undertaken in PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/) using pseudo-dosages, a fractional count of 0 to 1 alleles for each genotype weighted by imputation probability, within a linear regression (additive) model. A meta-analysis of all the groups was performed under a fixed-effects inversevariance model within METAL. 12 SNPs showing heterogeneity (p<0.05) were removed.
Two further analyses were performed, in which WMHV was additionally adjusted for hypertension alone or combined cardiovascular risk factors (hypertension, hypercholesterolemia, ever-smoker and diabetes). Individuals with missing cardiovascular risk factors were removed from the latter analysis resulting in an effective sample size of 1932.
The CHARGE consortium reported 62 SNPs significant at p<1x10 -5 in their discovery metaanalysis; 61 of these were typed or imputed in at least nine out of thirteen groups. A Z-score meta-analysis was performed of the association of these SNPs in CHARGE and the WMH cohorts. P-values were weighted by sample size consistent with the CHARGE report.
SNPs at locus 17q25
Six SNPs in high linkage disequilibrium at locus 17q25 were examined ( Figure 1 ). All SNPs were typed or imputed to high quality (r 2 ≥0.9) in all cohorts with the exception of MGHAffymetrix in which rs936393 was typed and only rs11869977 was well imputed (Supplementary   Table S3 ).
Allelic dosage for the most significant SNP was extracted and used in a conditional analysis of SNPs within a 100kb window using ProbABEL 13 , followed by meta-analysis within METAL.
Also a meta-analysis was performed of the association results of these SNPs in discovery CHARGE report 1 , Rotterdam replication report 2 and our WMH cohorts.
Genetic Risk Score
A genetic risk score (GRS) is a composite metric derived from a number of informative genetic variants associated with a phenotype of interest. We used SNPs highly associated with WMHV Table S3 ). Individuals with missing genotype(s) at these SNPs were excluded resulting in an effective sample size of 2564. The GRS was calculated by summing the risk allele doses and was not weighted because overall effect sizes are not available from the z-score meta-analysis employed in the CHARGE report.
Statistical Analysis
Statistical analyses were performed in R(http://R-project.org) and p<0.05 was considered significant. Within each group log-transformed WMHV normalized for TICV was adjusted for sex and age by obtaining standardized residuals from a linear regression model. The GRS both including, and excluding, the 17q25 locus was assessed as a predictor of adjusted WMHV by linear regression. The analyses were repeated with WMH additionally adjusted for hypertension, hypercholesterolemia, smoking and diabetes. Individuals with missing cardiovascular risk factors were removed from these analyses. The analyses were performed per center and meta-analyzed using inverse-variance method.
B. Association of 17q25 locus with lacunar stroke
Association between the 17q25 SNPs and lacunar stroke status was tested within METASTROKE, a consortium of ischemic stroke case-control GWA-studies. 14 1854 lacunar strokes and 51939 controls free of symptomatic stroke from twelve cohorts were included ( Table   2 ). Details of genotyping, quality-control, and imputation are available in the online supplement. Table S5 ). Association analyses were performed in each center by logistic regression assuming an additive model. Results were adjusted by genomic control factor, followed by meta-analysis under an inverse-variance weighted model.
RESULTS
A. Association of 17q25 locus with WMHV
All SNPs at the 17q25 locus were significantly associated with WMHV as a quantitative trait in a direction and magnitude of effect consistent with previous reports. Most associations remained significant after Bonferroni adjustment for multiple comparisons (p<0.008) except for rs1055129 (p=0.015) ( Table 3 ). The correction may be over-conservative given these SNPs are highly correlated (r 2 >0.85), with the exception of rs1055129, which is in moderate correlated with the others (r 2 ≈0.5) (Figure 1 ). The most significant SNP was rs9894383 (B=0.13 SE=0.04 p=0.0006) the risk allele was associated with a 13% (CI 6-22%) increase in the geometric mean of WMHV adjusted for age and sex ( Figure 2 ). There was no evidence of between-study heterogeneity. The results remained significant when adjusting for hypertension alone or cardiovascular risk factors (Supplementary Table S6 ).
Conditioning on rs9894383 did not reveal any other significant variants within a 100kb window. Figure 3 shows an approximate linear relationship between mean WMHV residuals and quintiles of the GRS with and without 17q25 locus. Supplementary Table S8 gives the mean GRS for each quintile.
B. Association of 17q25 locus with lacunar stroke
There was no association between the six SNPs and lacunar stroke status in the Metastroke casecontrol analysis (Table 3 ). The 17q25 SNPs were not associated with cardioembolic or large artery stroke (data not shown).
DISCUSSION
This study provides further support for an association between the 17q25 locus and WMH, and replication in ischemic stroke supports the hypothesis of shared genetic contribution to WMHV in community participants without stroke and ischemic stroke cases. The most significant SNP here was rs9894383 and meta-analysis with two previous reports 1,2 revealed a combined p-value of 1.0x10 -11 . Most SNPs within the 17q25 region were highly correlated and conditional analysis did not reveal more than one independent signal.
In contrast the 17q25 locus was not associated with another manifestation of SVD, lacunar stroke. This may suggest that any causal variant linked to this locus does not act by directly promoting small vessel arteriopathy or the type of arteriopathy primarily underlying lacunar infarction. The study was powered to detect an association with an odds ratio between 1.1-1.15.
Importantly, however, controls did not have brain imaging to exclude silent brain infarction, which is found in some 20% of healthy elderly 15 and this could have limited study power.
We performed a meta-analysis with the top SNPs reported by CHARGE; however, no novel loci reached genome-wide significance. To determine whether there were additional genetic variants shared by WMH occurring in community-participants without stroke and ischemic stroke, we calculated GRS excluding the 17q25 locus. This was a significant predictor of WMHV consistent with additional shared genetic variants. !
There are several genes in the 17q25 region; however, cis-expression quantitative trait loci, primarily of HapMap lymphoblastoid cells, implicate TRIM47. TRIM47 could modulate brain responses to ischemic injury as its RING domain confers protein ubiquitination, which promotes proteolysis and cellular homestasis. 16 Imbalance in ubiquitin-proteasome pathways is integral to cerebral ischemic injury mechanisms 17 and also evident in WMH expression profiles.
18
This study used volumetric MRI techniques, which have been demonstrated to be reliable and accurate [7] [8] [9] with good agreement across reading centers. A limitation is the variability in MRimaging protocols, resulting from the use of clinical imaging in these GWAS databases.
However, studies applying volumetric techniques have shown high reproducibility across acquisition protocols 8 and scanner models. 19 To minimize effects of MRI heterogeneity, centers were analyzed separately and WMHV z-scores were derived prior to association testing. We measured whole brain rather than regional WMHV and therefore could not investigate genetic differences between periventricular and subcortical WMH, which are suggested to have differing pathological, risk factor and functional associations. 4 Another limitation is that genotyping was performed on multiple platforms. However, top SNPs were imputed to a high quality with consistent allele frequencies.
In conclusion, our data provide further support for an association between the 17q25 locus and WMHV in patients with ischemic stroke. Future studies are warranted to explore these genetic associations in order to understand biological underpinnings of this complex cerebrovascular phenotype. The lack of association with lacunar stroke may suggest that the 17q25 locus does not act via promoting small vessel arteriopathy. 
STUDY POPULATIONS The Atherosclerosis Risk in Communities Study (ARIC)
The ARIC study is a prospective population-based study of atherosclerosis and clinical atherosclerotic diseases in 15,792 men and women, including 11,478 non-Hispanic white participants, drawn from 4 U.S. communities (Suburban Minneapolis, Minnesota; Washington County, Maryland; Forsyth County, North Carolina, and Jackson, Mississippi). Only selfidentified whites were included in the analyses. 1 Hospitalized strokes that occurred by December 31, 2007 (median follow-up, 18.7 years) were included in the analyses. This was determined by annual telephone interviews and obtaining hospital record for any hospitalizations. Moreover, all local hospitals annually provided lists of stroke discharges, which were surveyed for ARIC participant discharges. Details on quality assurance for ascertainment and classification of stroke are described elsewhere 2 . A stroke was classified as ischemic when a brain CT or MRI revealed acute infarction without hemorrhage. All definite ischemic strokes were further classified as lacunar, non-lacunar thrombotic, or cardioembolic on the basis of the recorded neuroimaging results. A stroke was classified as "lacunar" when 2 criteria were met: (1) typical location of the infarct (basal ganglia, brain stem, thalamus, internal capsule, or cerebral white matter); and (2) infarct size of ≤2 cm or unstated size. 3 Furthermore cases with a recognized source of emboli were excluded from this subtype. 4 ASGC controls were participants in the Hunter Community Study (HCS), a population-based cohort of individuals aged 55-85 years, predominantly of European Caucasian ancestry. 5 Briefly, participants were randomly selected from the NSW State electoral roll and contacted by mail between 2004 and 2007. Consenting participants completed detailed self-report questionnaires and attended the data collection centre, at which time a series of clinical measures were obtained. A total of 1280 HCS participants were genotyped for the current study.
Australian Stroke Genetics Collaborative (ASGC)
Bio-Repository of DNA in Stroke (BRAINS)
The Bio-Repository of DNA in Stroke (BRAINS) is an international study recruiting highly phenotyped patients with stroke. 6 For the purposes of the current work all patients were Caucasians. Diagnosis of stroke was confirmed using positive imaging (MRI or CT) and ischemic stroke subtypes were assigned using TOAST criteria, based on clinical, imaging and risk factor data. Controls were European-Ancestry, stroke-free participants from the shared WTCCC controls, a prospectively collected cohort of individuals born in 1958 (1958 Birth Cohort) (http://www.b58cgene.sgul.ac.uk/).
Cardiovascular Health Study (CHS)
The CHS is a population-based cohort study of risk factors for coronary heart disease (CHD) and stroke in adults ≥65 years conducted across four field centers in the United States. The original predominantly European Ancestry (self-reported as "white") cohort of 5,201 persons (4,964 whites) was recruited in 1989-1990 from a random sample of people on Medicare eligibility lists. 7 The discovery cohort was limited to those of self-reported European ancestry to reduce the possibility of confounding by population stratification. Participants were examined annually from enrollment to 1999, and continue to be contacted twice a year to identify potential cardiovascular events, including stroke. In addition, all hospitalizations were screened for potential stroke events and, when available, CT and/or MRI scans or reports were reviewed centrally. Final adjudication of the occurrence of stroke, stroke types, and subtypes was undertaken by vascular neurologists at a consensus conference using all available information. Strokes were classified as ischemic if there was imaging (CT or MRI within 4 weeks), surgical or autopsy evidence excluding a hemorrhage.
deCode Genetics
Cases, irrespective of age, were identified from a registry of individuals diagnosed with ischemic stroke or TIA at Landspitali University Hospital in Reykjavik, the only tertiary referral centre in Iceland, during the years 1993 to 2006. 8 The ischemic stroke or TIA diagnoses were based on standard WHO criteria and imaging evidence (either CT or MRI), and were clinically confirmed by neurologists. Eligible patients who survived the stroke were invited to participate the genetic study, either by attending a recruitment centre for deCODE's genetic studies, or they were visited at their home by a study nurse. Control subjects were participants from a large variety of genetic programs at deCODE. Individuals with confirmed stroke (identified by cross-matching with hospital lists), who had participated in genetic studies other than those of cardiovascular diseases (CVD) (but not participated in CVD studies) were excluded as controls.
The Genetics of Early Onset Stroke (GEOS) Study, Baltimore, USA
GEOS is a population-based case-control study designed to identify genes associated with earlyonset stroke in patients with first-ever ischemic stroke aged 15-49 years from the greater Baltimore-Washington area between 1992 and 2008. Only patients of European descent are included in this meta-analysis. Cases were identified through discharge surveillance from 59 participating hospitals and direct physician referral from a defined geographic region. Abstracted medical records were reviewed and adjudicated for ischemic stroke subtype by two neurologists, with discrepancies resolved by a third neurologist. Stroke was defined according to the WHO criteria and ischemic stroke was defined based on the criteria of the NINDS Stroke Data bank. 9 Cases had a head CT and/or brain MRI that was consistent with cerebral infarction. Visualization of the infarct was not required, only that no alternative etiology was identified. Ischemic stroke subtypes were assigned using TOAST criteria, based on clinical and imaging findings. Controls with no history of ischemic stroke were identified through random digit dialing and were frequency-matched to cases based on sex, age, geographic location and, during the later study periods, ethnicity.
The Heart and Vascular Health Study (HVH)
The setting for this study was Group Health (GH), a large integrated health care system in western Washington State. Data were utilized from an ongoing case-control study of incident myocardial infarction (MI) and stroke cases with a shared common control group. Methods for the study have been described previously [10] [11] and are briefly summarized below. All study participants were GH members and aged 30-79 years. MI and stroke cases were identified from hospital discharge diagnosis codes and were validated by medical record review. Controls were a random sample of GH members frequency matched to MI cases on age (within decade), sex, treated hypertension, and calendar year of identification. The index date for controls was a computer-generated random date within the calendar year for which they had been selected. For stroke cases, the index date was the date of admission for the first acute stroke. Participants were excluded if they were recent enrollees at GH, had a history of prior stroke, or if the incident event was a complication of a procedure or surgery.
Trained medical record abstractors collected eligibility and risk factor information from a review of the GH medical record using only data available prior to the index date and through a telephone interview. Medication use was ascertained using computerized GH pharmacy records. A venous blood sample was collected from all consenting subjects, and DNA was extracted from white blood cells using standard procedures. Diagnostic criteria for ischemic stroke were adopted from the Cardiovascular Health Study. Ischemic stroke cases satisfied one or more of the following criteria: (a) Focal deficit, without evidence of blood on CT or MRI, (b) Focal deficit, with mottled appearance in the appropriate location on CT, or (c) surgery or autopsy evidence of infarction. Subtyping of lacunar stroke ("SVD") required either: (a) CT/MRI demonstrates a deep area of infarction (decreased density) less than 2 cm. across, or (b) A normal CT, but the clinical syndrome is typical of a lacunar infarction, that is: a pure motor stroke, a pure sensory stroke, hemiparesis plus ataxia, or dysarthria plus a clumsy hand (c) Exclude cases with a recognized source of emboli or large vessel atherosclerosis.
Siblings With Ischemic Stroke Study (SWISS)
Siblings with Ischemic Stroke Study (SWISS) was a prospective, multicenter affected sibling pair study of first-ever or recurrent ischemic stroke. 12 Probands were recruited from 70 clinical centers across the US and Canada. Ischemic stroke affected and unaffected siblings were recruited primarily using proband-initiated contact. All affected individuals had WHO-defined stroke confirmed by a study neurologist to be ischemic on the basis of head CT or brain MRI. All confirmed cases of ischemic stroke were further classified by a study neurologist using the TOAST criteria. 4 Peripheral blood DNA samples were collected between October 2000 and December 2009.
The Ischemic Stroke Genetics Study (ISGS)
Ischemic Stroke Genetics Study (ISGS) was a 5-center, prospective, case-control study of firstever ischemic stroke cases and concurrently enrolled controls individually matched for age, sex and recruitment site. 13 All affected individuals had WHO-defined stroke confirmed by a study neurologist to be ischemic on the basis of head CT or brain MRI. All confirmed cases of ischemic stroke were further classified by a centralized phenotype committee consisting of study neurologists using the TOAST as well as other standardized systems. Peripheral blood DNA samples were collected between May 2003 and September 2008.
Genes Affecting Stroke Risk and Outcome Study (GASROS)
Cases were all consecutive patients aged ≥ 18 years presenting with ischemic stroke and admitted to the Massachusetts General Hospital (MGH) Stroke Unit through the Emergency Department, or evaluated in the MGH Neurology outpatient clinics, as well as on the inpatient Medical and Vascular Surgical services from January 2003 to July 2008.
14 Only patients of European ancestry (confirmed by principal component analysis using genome-wide SNP data) were included in the present analysis. Ischemic stroke was defined as either (1) a radiographically proven (head CT or MRI) infarct associated with the appropriate clinical stroke syndrome, or (2) a fixed neurological deficit persisting more than 24 hours, consistent with a vascular pattern of involvement and without radiographic evidence of demyelinating disease, or other non-vascular structural disease. All subjects were evaluated by a neurologist upon presentation and clinical and laboratory data were collected during the admission for qualifying ischemic stroke event. All patients had brain imaging (CT and/or MRI) as well as ancillary diagnostic investigations where clinically relevant to qualify ischemic stroke event. Diagnostic work-up included: head CT (100%), brain MRI (90%), cervical and intracranial vessel imaging using CTA or MRA (75%), carotid and/or transcranial ultrasound (24%), echocardiography (86%), and Holter monitoring (16%). Controls were recruited among the stroke-free adults presenting to the MGH outpatient clinics and matched with the stroke cases on the basis of age, sex and ancestry information obtained from principal component analysis of GWAS data.
Milan
This study includes consecutive Italian patients referred to Besta Institute from 2000 to 2009 with stroke and included in the Besta Cerebrovascular Diseases Registry (CEDIR). 15 Ischemic stroke cases, first ever or recurrent, confirmed on brain imaging, were selected for this study. All cases were of self reported Caucasian ancestry and had clinically relevant diagnostic workup performed. All cases were phenotyped by an experienced stroke neurologist according to TOAST criteria, based on relevant clinical imaging and available information on cardiovascular risk factors. Controls are Italian individuals enrolled within the PROCARDIS Study, with no personal or sibling history of coronary heart disease before age 66 years.
Wellcome Trust Case-Control Consortium 2 (WTCCC2)
The WTCCC2 samples were genotyped as part of the WTCCC 2 ischemic stroke study. Stroke cases included samples recruited by investigators at from three centers in the UK (St. George's Oxford and Edinburgh) and one centre in Germany, University and Klinikum Großhadern, Ludwig-Maximilians-University, Munich. 15 The , from a single Stroke Unit with a high rate of MR imaging (>80%) (n=1383). All subjects were over 18 years of age, of self-reported European ancestry and with a diagnosis of ischaemic stroke classified according to TOAST by an experienced neurologist or stroke physician. All patients had brain imaging (CT and/or MRI) as well as ancillary diagnostic investigations where clinically relevant. All cases were of self reported Caucasian ancestry.
Controls for the UK samples were drawn from shared WTCCC controls obtained from the 1958 Birth Cohort. This is a prospectively collected cohort of individuals born in 1958 (http://www.b58cgene.sgul.ac.uk/), and ascertained as part of the national child development study (http://www.cls.ioe.ac.uk/). Data from this cohort are available as a common control set for a number of genetic and epidemiological studies. For the German samples controls were Caucasians of German origin participating into the population KORAgen study (http://epi.gsf.de/kora-gen/index_e.php). This survey represents a gender-and age stratified random sample of all German residents of the Augsburg area and consists of individuals 25 to 74 years of age, with about 300 subjects for each 10-year increment. All controls were free of a history of stroke or transient ischemic attack.
GENOTYPING, IMPUTATION & QUALITY CONTROL IN METASTROKE COHORTS The Atherosclerosis Risk in Communities Study (ARIC)
Genotyping was performed with the GeneChip SNP Array 6.0 (Affymetrix). Subject specific quality control filters included filters for call rate, heterozygosity, sex mismatch. SNP specific quality control filters included filters for call rate, minor allele frequency (MAF), HardyWeinberg equilibrium (HWE), and differential missingness by outcome or genotype. The set of genotyped input SNPs used for imputation was selected based on high quality GWA data. We used a call-rate >95%, HWE p-value>5x10 -6 ; MAF>0.01. A total of 704,588 SNPs passing quality control (QC) criteria were used for imputation, which was performed with the MaCH (http://www.sph.umich.edu/csg/yli/mach/index.html) v1.0.16 software.
Australian Stroke Genetics Collaborative (ASGC)
The ASGC sample was genotyped using the Illumina HumanHap610-Quad array. Quality control excluded SNPs with genotype call rate <0.95, deviation from HWE P<1×10 -6 or MAF <0.01. At the individual level, samples were excluded if: (i) genotype call rate <95%; ii) genome-wide heterozygosity < 23.3% or > 27.2%; iii) disconcordant clinical and genotypic gender; iv) an inferred first-or second-degree relative in the sample based on pair-wise allele sharing estimates (estimated genome proportion shared identical by descent (IBD): pi-hat >0.1875). Principal components analysis (PCA) was performed, incorporating genotype data from Phase 3 HapMap populations (CEU, CHB, JPT, TSI, YRI) in order to identify and remove non-European ancestry individuals. Following quality control, 1162 cases and 1244 controls were available for association analyses at 551,514 SNPs.
Genotype imputation in the filtered sample was performed using MACH v1.0.16, based on HapMap Phase 2 (release 24) phased haplotypes for European-ancestry (CEU) samples. Subsequent quality control excluded imputed SNPs with MAF <0.01 or ratio of observed dosage variance to expected binomial variance of r 2 <0.3.
Bio-Repository of DNA in Stroke (BRAINS)
The BRAINS sample was genotyped using the Illumina HumanHap610-Quad array. Quality control excluded SNPs not genotyped on all case and control collections and SNPs with genotype call rate <0.95, deviation from Hardy-Weinberg equilibrium (P<1×10 -6 ) or minor allele frequency <0.01. Individual samples were excluded due to low call rates (<95%), gender discrepancy, unexpected relatedness or evidence of non-European ancestry.
Genotype imputation was performed using MACH v1.0.16 based on HapMap Phase 2 CEU samples (release #22). Quality control removed imputed SNPs with MAF <0.01 or ratio of observed dosage variance to expected binomial variance of r 2 <0.3.
Cardiovascular Health Study (CHS)
In 2007-2008, genotyping was performed at the General Clinical Research Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip system on 3980 CHS participants who were free of CVD at baseline, consented to genetic testing, and had DNA available for genotyping.
A total of 1908 persons were excluded from the GWAS study sample due to the presence at study baseline of coronary heart disease, congestive heart failure, peripheral vascular disease, valvular heart disease, stroke or transient ischemic attack or lack of available DNA. Because the other cohorts were predominantly of European Ancestry, the African American participants were excluded from this analysis to reduce the possibility of confounding by population structure. Participants were also excluded for sex mismatch (discordance with genotyping) or call rate ≤ 95%. To date, genotyping has been successful among 3,271 of 3,373 white participants on whom genotyping was attempted; the latter constitute the CHS sample for this study. In CHS, the following exclusions were applied to identify a final set of 306,655 autosomal SNPs: call rate < 97%, Hardy-Weinberg p-value < 10 -5 , > 2 duplicate errors or Mendelian inconsistencies (for reference CEPH trios), heterozygote frequency = 0, SNP not found in HapMap. Imputation was performed using BIMBAM v0.99 (http://www.bcm.edu/cnrc/mcmcmc/bimbam/) with reference to HapMap CEU using release 22, build 36 using one round of imputations and the default expectation-maximization warm-ups and runs. For each imputed SNP a reliability of imputation was estimated as the ratio of the observed dosage variance to the expected binomial dosage variance.
deCODE Genetics
The Icelandic chip-genotyped samples were assayed with the Illumina Human Hap300, Hap CNV370, Hap 610, 1M or Omni-1 Quad bead chips at deCODE genetics. SNPs were excluded if (i) yield was lower than 95%, (ii) MAF < 0.01 (iii) significant deviation from HWE in controls p< 0.001, (iv) an excessive inheritance error rate (> 0.001) was produced or (v) there was a substantial difference in allele frequency between chip types (from just a single chip if that resolved all differences, but from all chips, otherwise). All samples with a call rate below 97% were excluded from the analysis. Imputation was performed using IMPUTE (https://mathgen.stats.ox.ac.uk/impute/impute.html).
The Genetics of Early Onset Stroke (GEOS) Study, Baltimore, USA Samples were genotyped at the Johns Hopkins Center for Inherited Disease Research (CIDR), and using the Illumina HumanOmni1-Quad_v1-0_B BeadChip. Case and control samples were balanced across the plates. Allele cluster definitions for each SNP were determined using Illumina BeadStudio Genotyping Module version 3.3.7, Gentrain version 1.0 and the combined intensity data from all released samples. Genotypes were not called if the quality threshold (GenCall score) was below 0.15.
All samples had a genotype call rate > 98%. Genotyping concordance rate was 99.996% based on study duplicates. Samples were excluded due to unexpected duplicates, gender discrepancy, unexpected relatedness or evidence of non-European ancestry based on principal components analysis. Individual SNPs were excluded from analysis if they had excessive deviation from HWE in controls p< 1.0x10 -6 , genotype call rates <97.5% or MAF < 0.01.
The Heart and Vascular Health Study (HVH)
Genotyping was performed at Cedars-Sinai using the Illumina 370CNV BeadChip and called using the Illumina BeadStudio software. Samples were excluded from analysis for sex mismatch or call rate < 95%. The following exclusions were applied to identify a final set of 301,321 autosomal SNPs: call rate < 97%, HWE P < 10 -5 , > 2 duplicate errors or Mendelian inconsistencies (for reference CEPH trios), heterozygote frequency = 0, SNP not found in HapMap, inconsistencies across genotyping batches. Imputation was performed using BIMBAM with reference to HapMap CEU using release 22 (build 36). SNPs were excluded from analysis for variance on the allele dosage ≤0.01.
Logistic regression was used to investigate the association of each SNP with the risk of stroke adjusting for the matching factors of age, sex, hypertension status and index year. Linear additive models were used with robust standard errors and estimated risk for each additional copy of the variant allele, using R.
The Ischemic Stroke Genetics Study (ISGS)/ Siblings With Ischemic Stroke Study (SWISS)
SWISS and ISGS cases were genotyped using Illumina 650K Quad arrays at the Department of Molecular Neuroscience and Reta Lilla Weston Laboratories, Institute of Neurology, University College London. Controls utilized in this study are participants of the Baltimore Longitudinal Study of Aging (BLSA). No known first degree relatives with stroke or other neurological disease are included in the controls for the present analysis. Controls were genotyped using
